Daniela Peritore
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniela Peritore has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
P. Fiaschetti
Centro Nazionale Trapianti, Rome, Italy
8 shared publicationsL. Rizzato
Italian National Transplant Center, Istituto Superiore di Sanità, Rome, Italy
7 shared publicationsA. Nanni Costa
Centro Nazionale Trapianti, Rome, Italy
6 shared publicationsA. Oliveti
Centro Nazionale Trapianti, Rome, Italy
6 shared publications- Andrea Ricci
Italian National Transplant Centre, Italian National Institute of Health, Rome, Italy
6 shared publications - Renzo Pretagostini
Department of General Surgery and Transplantation "P. Stefanini", Sapienza University of Rome, Italy
6 shared publications
Latest Publications
- Open Access
- 1 December 2025
- Published by Pacini Editore in European Journal of Transplantation
- Vol. 3 (2) , 86-98
ORGAN TRANSPLANTATION FROM DONORS WITH MALIGNANCIES: RISK ASSESSMENT AND CLINICAL OUTCOMES
Background. Using organs from donors with malignant diseases raises concerns about transferring cancer to recipients, requiring careful risk assessment and monitoring. This paper aims to analyze the risk of cancer transmission in recipients of solid organ transplants (SOT) from donors with malignancies in Italy. Methods. This is a retrospective review of all deceased donors and recipients of solid organ transplants recorded in the Italian Transplant Information System (SIT) between January 1, 2016, and December 31, 2024. Donor and recipient characteristics were examined, including the donor's oncological risk category, determined based on national guidelines and second opinions. Cancer transmission was classified as proven, probable, possible (or suspected), or excluded based on previous evidence. Results. During the study period, 32,307 transplants were performed from 12,962 donors, with a total of 1,360 transplants (4.2%) from 747 donors (5.7%) who had at least one malignancy. In 712 donors (5.5%), the diagnosis was made during procurement, while in 34 donors (0.2%), it was discovered after transplantation, and in only one case (0.008%), it was an occult condition. Cancer transmission was confirmed in 4 recipients (0.03%), suspected in 44 (0.33%), and ruled out in 13 (0.1%). The per-transplant risk of cancer transmission was 0.012% for the overall cohort of recipients (4/32,307), and 0.29% among recipients of donors with malignancies (4/1,360). The fatality rate of donor-transmitted cancers was 0.006% (2/32,307) in the overall transplant cohort, and 0.14% (2/1,360) in the group of recipients with donors who had malignancies. Conclusions. With proper risk assessment, second-opinion consultation, and post-transplant surveillance, organs from donors with malignancies can be used safely, expanding the donor pool without significantly increasing recipient cancer risk. Vigilant national reporting and standardized protocols are essential for reducing transmission risk.
- 1 December 2025
- Published by Pacini Editore in European Journal of Transplantation
- Vol. 3 (2) , 86-98
Open AccessORGAN TRANSPLANTATION FROM DONORS WITH MALIGNANCIES: RISK ASSESSMENT AND CLINICAL OUTCOMES
Background. Using organs from donors with malignant diseases raises concerns about transferring cancer to recipients, requiring careful risk assessment and monitoring. This paper aims to analyze the risk of cancer transmission in recipients of solid organ transplants (SOT) from donors with malignancies in Italy. Methods. This is a retrospective review of all deceased donors and recipients of solid organ transplants recorded in the Italian Transplant Information System (SIT) between January 1, 2016, and December 31, 2024. Donor and recipient characteristics were examined, including the donor's oncological risk category, determined based on national guidelines and second opinions. Cancer transmission was classified as proven, probable, possible (or suspected), or excluded based on previous evidence. Results. During the study period, 32,307 transplants were performed from 12,962 donors, with a total of 1,360 transplants (4.2%) from 747 donors (5.7%) who had at least one malignancy. In 712 donors (5.5%), the diagnosis was made during procurement, while in 34 donors (0.2%), it was discovered after transplantation, and in only one case (0.008%), it was an occult condition. Cancer transmission was confirmed in 4 recipients (0.03%), suspected in 44 (0.33%), and ruled out in 13 (0.1%). The per-transplant risk of cancer transmission was 0.012% for the overall cohort of recipients (4/32,307), and 0.29% among recipients of donors with malignancies (4/1,360). The fatality rate of donor-transmitted cancers was 0.006% (2/32,307) in the overall transplant cohort, and 0.14% (2/1,360) in the group of recipients with donors who had malignancies. Conclusions. With proper risk assessment, second-opinion consultation, and post-transplant surveillance, organs from donors with malignancies can be used safely, expanding the donor pool without significantly increasing recipient cancer risk. Vigilant national reporting and standardized protocols are essential for reducing transmission risk.
- 2 November 2024
- Published by Springer Nature
- p. 653-674
Data Collection and Quality Control: The Role of Scientific Societies, OPOs, and Governmental Agencies
- 2 November 2024
- Published by Springer Nature
- p. 653-674
Data Collection and Quality Control: The Role of Scientific Societies, OPOs, and Governmental Agencies
- Open Access
- 15 October 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (S1) , e14398
Perspective on donor‐derived infections in Italy
Background: Expected and unexpected donor‐derived infections (DDI) are a rare event in solid organ transplant (SOT) recipients but are potentially associated with significant morbidity and mortality. To assure the microbial safety of transplantation, both national guidelines and the current, regional, and local epidemiology of infectious diseases must be considered.Methods: In the present paper the strategies adopted by the Italian National Center for Transplantation (CNT) since 2003 and their evolution to guarantee the safety of organ transplantation are reported. Starting in 2012 mandatory reporting to the CNT of all adverse reactions was started. The number and type of DDI reported to the CNT are currently being analyzed.Results: The infectious diseases second opinion has written and updated the guidelines on the safety of organs for transplantation and supported the Italian transplant network for the use of organs from donors with suspected or documented potentially transmissible infections.Conclusion: A transplant safety network was developed in Italy in 2003 and has been updated according to the evolving knowledge and the changing epidemiology. This is an evolving field, and a continuous update of the recommendation is needed.
- 15 October 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (S1) , e14398
Open AccessPerspective on donor‐derived infections in Italy
Background: Expected and unexpected donor‐derived infections (DDI) are a rare event in solid organ transplant (SOT) recipients but are potentially associated with significant morbidity and mortality. To assure the microbial safety of transplantation, both national guidelines and the current, regional, and local epidemiology of infectious diseases must be considered.Methods: In the present paper the strategies adopted by the Italian National Center for Transplantation (CNT) since 2003 and their evolution to guarantee the safety of organ transplantation are reported. Starting in 2012 mandatory reporting to the CNT of all adverse reactions was started. The number and type of DDI reported to the CNT are currently being analyzed.Results: The infectious diseases second opinion has written and updated the guidelines on the safety of organs for transplantation and supported the Italian transplant network for the use of organs from donors with suspected or documented potentially transmissible infections.Conclusion: A transplant safety network was developed in Italy in 2003 and has been updated according to the evolving knowledge and the changing epidemiology. This is an evolving field, and a continuous update of the recommendation is needed.
- 5 August 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (9) , e14769
Organ donation from patients with a rare disease is often safe: the italian guidelines
Although a disease is defined as rare when it has a prevalence of less than 1:2000, the overall prevalence of rare diseases in the population is greater than 1%. Among potential organ donors, a similar frequency is observed. To date, guidelines have not been established, and operational decisions have been made empirically, case‐ by‐case, based on the experience and expertise of clinicians. For this reason, the Italian Superior Health Council (CSS) has appointed a working Group to address “patients with a rare disease as potential organ donors,” with the aim of devising recommendations for the management of transplant cases in which the donors have a rare disease. This group evaluated 493 diseases (10% of all rare diseases, including over 95% of patients with a rare disease) to deliver a technical report dealing with the suitability of organ donation and transplantation, with a focus on the organs most frequently used, including kidney, liver, heart, lung, and pancreas. This work has made it clear that a rare disease “per se” does not contraindicate organ donation at all. Indeed, in donors affected by a rare disease, almost 80% of the organs are suitable for transplantation, approximately 7% are unsuitable, and approximately 14% are suitable as non‐standard with an acceptable risk.
- 5 August 2022
- Published by Wiley in Clinical Transplantation
- Vol. 36 (9) , e14769
Organ donation from patients with a rare disease is often safe: the italian guidelines
Although a disease is defined as rare when it has a prevalence of less than 1:2000, the overall prevalence of rare diseases in the population is greater than 1%. Among potential organ donors, a similar frequency is observed. To date, guidelines have not been established, and operational decisions have been made empirically, case‐ by‐case, based on the experience and expertise of clinicians. For this reason, the Italian Superior Health Council (CSS) has appointed a working Group to address “patients with a rare disease as potential organ donors,” with the aim of devising recommendations for the management of transplant cases in which the donors have a rare disease. This group evaluated 493 diseases (10% of all rare diseases, including over 95% of patients with a rare disease) to deliver a technical report dealing with the suitability of organ donation and transplantation, with a focus on the organs most frequently used, including kidney, liver, heart, lung, and pancreas. This work has made it clear that a rare disease “per se” does not contraindicate organ donation at all. Indeed, in donors affected by a rare disease, almost 80% of the organs are suitable for transplantation, approximately 7% are unsuitable, and approximately 14% are suitable as non‐standard with an acceptable risk.
- 1 June 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (6) , 1524-1527
Post–COVID-19 Lung Transplantation Italian Pivotal Protocol: Some Ethical Considerations
- 1 June 2022
- Published by Elsevier in Transplantation Proceedings
- Vol. 54 (6) , 1524-1527
Post–COVID-19 Lung Transplantation Italian Pivotal Protocol: Some Ethical Considerations
- 11 February 2022
- Published by Springer Nature
- p. 1-22
Data Collection and Quality Control: The Role of Scientific Societies, OPOs, and Governmental Agencies
- 11 February 2022
- Published by Springer Nature
- p. 1-22
Data Collection and Quality Control: The Role of Scientific Societies, OPOs, and Governmental Agencies
- 1 June 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (5) , 1522-1524
Rare Disease Patients as Potential Organ Donors
- 1 June 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (5) , 1522-1524
Rare Disease Patients as Potential Organ Donors
- 1 May 2017
- Published by Elsevier in Transplantation Proceedings
- Vol. 49 (4) , 692-694
Optimizing the Use of Available Lungs
- 1 May 2017
- Published by Elsevier in Transplantation Proceedings
- Vol. 49 (4) , 692-694
Optimizing the Use of Available Lungs
- 1 May 2017
- Published by Elsevier in Transplantation Proceedings
- Vol. 49 (4) , 622-628
Transport of Human Organs in Italy: Location, Time, and Performances
- 1 May 2017
- Published by Elsevier in Transplantation Proceedings
- Vol. 49 (4) , 622-628
Transport of Human Organs in Italy: Location, Time, and Performances